LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for:
1.
Treatment of adult patients with very high elevations of serum triglyceride levels
(Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not
respond adequately to a determined dietary effort to control them. Patients who
present such risk typically have serum triglycerides over 2000 mg/dL and have
elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V
hyperlipidemia).
Reducing the risk of developing coronary heart disease only in Type IIb patients
without history of or symptoms of existing coronary heart disease who have had an
inadequate response to weight loss, dietary therapy, exercise, and other
pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to
reduce LDL-and raise HDL-cholesterol) and who have the following triad of lipid
abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol
and elevated triglycerides.
